How to sequence treatment in relapsed ovarian cancer.
Numerous disease- and patient-related factors must be considered when selecting systemic therapy for recurrent ovarian cancer. Anti-angiogenics (bevacizumab) and poly(ADP-ribose) polymerase inhibitors (olaparib, niraparib and rucaparib) have an important role as maintenance of platinum-based chemotherapy for recurrent disease and their use in the first-line setting of advanced-stage disease is becoming established. As previous exposure to none, one or both of these drug classes is integral to selecting next therapy, front-line use impacts on options available to treat recurrent disease. A key strategy to delay platinum resistance and improve prognosis of recurrent disease is to alternate treatments with different mechanisms of action. The multiple mechanisms of trabectedin and its complementarity with platinum allow intercalation between platinum regimens in potentially platinum-responsive patients with recurrent disease.
['Pignata|Sandro|S|', 'Cecere|Sabrina Chiara|SC|']
D020533:Angiogenesis Inhibitors D000971:Antineoplastic Combined Chemotherapy Protocols D005260:Female D006801:Humans D009364:Neoplasm Recurrence, Local D010051:Ovarian Neoplasms D000067856:Poly(ADP-ribose) Polymerase Inhibitors D017410:Practice Guidelines as Topic
ovarian cancer recurrent platinum-based chemotherapy trabectedin PARP inhibitors antiangiogenics